Basis: FMP quote price / unrounded FMP forward EPS in the trading currency, available after its recorded retrieval time. Source: stored company filings and market data; unavailable inputs remain N/A.
The forward PE ratio is N/A as of 2026-10-06T19:15:33.197Z.
Consensus retrieved: 2026-10-06T08:18:07.056Z. This records retrieval, including cache reads, rather than vendor publication. The calculation uses the separately dated price and estimate available at its as-of time.
Calculation as of: 2026-10-06T19:15:33.197Z.
Quote observation: 2026-10-06T19:15:25.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: 5d81df243028a463df18dadfb6b81954a95dec5b5738e9798e17a16434fd93e0
Forward PE Ratio (N/A) = Dated Quote Price ($2.04) / Consensus Forward EPS ($-1.53)
FORWARD PE RATIO
N/A
Acumen Pharmaceuticals, Inc.
Market Cap
$147.34M
Forward PE Ratio
N/A
| NAME | MARKET CAP | FORWARD PE RATIO |
|---|---|---|
| Acumen Pharmaceuticals, Inc. (ABOS) | $147.34M | N/A |
| Voyager Therapeutics, Inc. (VYGR)vs › | $147.73M | N/A |
| NervGen Pharma Corp. Common stock (NGEN)vs › | $148.43M | N/A |
| Cardiol Therapeutics Inc. (CRDL)vs › | $148.70M | N/A |
| ALX Oncology Holdings Inc. (ALXO)vs › | $148.83M | N/A |
| Anavex Life Sciences Corp. (AVXL)vs › | $148.83M | N/A |
| Codexis, Inc. (CDXS)vs › | $148.97M | N/A |
| Veraxa Biotech Holding AG (VRXA)vs › | $149.89M | N/A |
| Korsana Biosciences, Inc. (KRSA)vs › | $144.56M | N/A |
| Protara Therapeutics, Inc. (TARA)vs › | $143.51M | N/A |
Trailing P/E
N/A
reported TTM EPS
Forward P/E
N/A
consensus EPS · fiscal year ending 2026-12-31
At the dated quote price of $2.04, each upcoming fiscal year's consensus EPS implies a different multiple — how quickly the price is "paid down" by expected earnings if the estimates hold.
| Fiscal year end | Consensus EPS | Estimate range | Analysts | Implied P/E |
|---|---|---|---|---|
| 2026-12-31 | $-1.53 | $-1.64 – $-1.45 | 3 | n/m |
| 2027-12-31 | $-1.48 | $-1.93 – $-1.22 | 3 | n/m |
| 2028-12-31 | $-1.18 | $-1.57 – $-0.79 | 2 | n/m |
Source: FMP analyst consensus estimates, refreshed with the daily precompute. "n/m" = the consensus EPS is not positive, so a multiple is undefined. There is no forward P/E history chart here because charting one would require the estimates as they stood in the past, which we do not store — see the trailing P/E history for how the realized multiple has moved.
PE Ratio = Share Price / Diluted EPS (TTM)
The price-to-earnings ratio measures how much investors pay for each dollar of trailing earnings. A lower PE can indicate a cheaper valuation; a higher PE implies higher growth expectations.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
